Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Comprehensive Eye Drop Recall List for 2023
Since February 2023, the FDA and various companies have been actively initiating recalls of eye drops and ointments due to concerns about potential bacterial contamination. The recalls, motivated by the risk of tainted products, have been steadily increasing, underscoring the…
Astellas Signs Ophthalmic Gene Therapy Deal with 4DMT
Astellas Pharma has signed a license agreement that grants them the rights to utilize the intravitreal retinotropic R100* vector, developed by 4D Molecular Therapeutics (4DMT). This agreement enables Astellas to target one specific genetic target associated with rare monogenic ophthalmic…
Waterloo University’s Drug for AMD and DME
Researchers have successfully developed a groundbreaking synthetic protein to treat macular degeneration and other currently incurable eye diseases leading to blindness in millions of individuals. This pioneering drug, currently undergoing human trials, is the first of its kind. With over…
What Is Bull’s Eye Maculopathy and How to Manage It
What Is Bull’s Eye Maculopathy? Bull’s Eye Maculopathy is a specific form of retinal disease characterized by changes in the pigmentation of the macular region of the retina, often presenting as a ‘bull’s eye’ pattern. The macula is the central…
SYFOVRE® Secures Permanent J-Code from CMS
The U.S. Centers for Medicare & Medicaid Services (CMS) have officially designated a specific J-code (J2781) for Apellis Pharmaceuticals’ Syfovre (pegcetacoplan injection), marking it as the first treatment for geographic atrophy (GA) secondary to age-related macular degeneration. This J-code for…
Iveric Bio’s Izervay for Geographic Atrophy Approved by FDA
Parent company Astellas Pharma announced that Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). As a new complement C5 inhibitor, Izervay stands out as the sole…
Best Treatment for Uveitic Macular Edema Identified
Repeat corticosteroid injections were found to be more effective in improving vision for individuals with persistent or recurrent uveitis-related macular edema compared to methotrexate or ranibizumab intravitreal injections, according to a recent clinical trial. The corticosteroid treatment exhibited superior results…
Study Unveils the Dynamic Architecture of the Human Eye
The retinal pigment epithelium (RPE) and choroid, located behind the human retina, play crucial roles in vision, encompassing functions such as light absorption and providing oxygenated blood to photoreceptor cells. However, our current understanding of gene expressions within these cells…
Aegis and Northwell Launch AI Company Optain
Ascertain, a joint venture between Aegis Ventures and Northwell Holdings, has raised $12 million in seed funding to launch Optain, an AI company that utilizes retinal imaging for early disease detection and prevention. Optain’s AI technology analyzes data from a…
Tenpoint Therapeutics Launches with $70M Financing
Tenpoint Therapeutics, a biotechnology company focused on vision-restoring engineered cell-based therapeutics and in vivo reprogramming for degenerative ocular diseases, has announced its launch with a $70 million Series A financing. The funding will be used to develop the company’s regenerative…